PE20130254A1 - Factor viii conjugado para coagulacion de la sangre - Google Patents

Factor viii conjugado para coagulacion de la sangre

Info

Publication number
PE20130254A1
PE20130254A1 PE2012002104A PE2012002104A PE20130254A1 PE 20130254 A1 PE20130254 A1 PE 20130254A1 PE 2012002104 A PE2012002104 A PE 2012002104A PE 2012002104 A PE2012002104 A PE 2012002104A PE 20130254 A1 PE20130254 A1 PE 20130254A1
Authority
PE
Peru
Prior art keywords
group
factor viii
link
fviii
refers
Prior art date
Application number
PE2012002104A
Other languages
English (en)
Spanish (es)
Inventor
William Henry
Original Assignee
Cantab Biopharmaceuticals Patent Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42289987&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20130254(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Cantab Biopharmaceuticals Patent Ltd filed Critical Cantab Biopharmaceuticals Patent Ltd
Publication of PE20130254A1 publication Critical patent/PE20130254A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/37—Factors VIII
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays or needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
PE2012002104A 2010-04-30 2011-04-28 Factor viii conjugado para coagulacion de la sangre PE20130254A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1007357.5A GB201007357D0 (en) 2010-04-30 2010-04-30 Conjugated factor VIII

Publications (1)

Publication Number Publication Date
PE20130254A1 true PE20130254A1 (es) 2013-03-16

Family

ID=42289987

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2012002104A PE20130254A1 (es) 2010-04-30 2011-04-28 Factor viii conjugado para coagulacion de la sangre

Country Status (26)

Country Link
US (1) US20130150302A1 (enExample)
EP (1) EP2563402A1 (enExample)
JP (1) JP5870088B2 (enExample)
KR (1) KR20130055619A (enExample)
CN (1) CN102939108A (enExample)
AP (1) AP2012006575A0 (enExample)
AU (1) AU2011247147B2 (enExample)
BR (1) BR112012027590A2 (enExample)
CA (1) CA2797058A1 (enExample)
CL (1) CL2012003039A1 (enExample)
CO (1) CO6660443A2 (enExample)
CR (1) CR20120579A (enExample)
EA (1) EA201290938A1 (enExample)
EC (1) ECSP12012314A (enExample)
GB (2) GB201007357D0 (enExample)
IL (1) IL222566A (enExample)
MX (1) MX2012012683A (enExample)
MY (1) MY160922A (enExample)
NI (1) NI201200160A (enExample)
NZ (1) NZ603939A (enExample)
PE (1) PE20130254A1 (enExample)
PH (1) PH12012502150A1 (enExample)
RU (1) RU2012144555A (enExample)
SG (1) SG184906A1 (enExample)
WO (1) WO2011135307A1 (enExample)
ZA (1) ZA201208989B (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2101821T3 (da) 2006-12-15 2014-10-06 Baxter Healthcare Sa Faktor VIIA-(poly)sialinsyre-konjugat med forlænget halveringstid in vivo
US8642737B2 (en) 2010-07-26 2014-02-04 Baxter International Inc. Nucleophilic catalysts for oxime linkage
EP3081233B1 (en) 2009-07-27 2020-12-23 Baxalta GmbH Glycopolysialylation of proteins other than blood coagulation proteins
RU2744370C2 (ru) 2009-07-27 2021-03-05 Баксалта Инкорпорейтед Конъюгаты белков свертывания крови
US8809501B2 (en) 2009-07-27 2014-08-19 Baxter International Inc. Nucleophilic catalysts for oxime linkage
BR112012001814A8 (pt) 2009-07-27 2018-02-06 Baxalta GmbH Conjugados de proteína de coagulação sanguínea
ES2800983T3 (es) 2010-12-22 2021-01-07 Baxalta GmbH Materiales y métodos para conjugar un derivado de ácido graso soluble en agua con una proteína
HK1200695A1 (en) * 2012-04-16 2015-08-14 Cantab Biopharmaceuticals Patents Limited Optimised subcutaneous therapeutic agents
GB201417589D0 (en) 2014-10-06 2014-11-19 Cantab Biopharmaceuticals Patents Ltd Pharmaceutical Formulations
GB201518170D0 (en) 2015-10-14 2015-11-25 Cantab Biopharmaceuticals Patents Ltd Colloidal particles for subcutaneous administration with intravenous administration of therapeutic agent
GB201518171D0 (en) 2015-10-14 2015-11-25 Cantab Biopharmaceuticals Patents Ltd Colloidal particles for topical administration with therapeutic agent
GB201518172D0 (en) 2015-10-14 2015-11-25 Cantab Biopharmaceuticals Patents Ltd Colloidal particles for use in medicine
KR20190086269A (ko) * 2018-01-12 2019-07-22 재단법인 목암생명과학연구소 체내 지속형 재조합 당단백질 및 이의 제조방법
CN117467019A (zh) 2018-05-18 2024-01-30 郑州晟斯生物科技有限公司 改进的fviii融合蛋白及其应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1596887B1 (en) * 2003-02-26 2022-03-23 Nektar Therapeutics Polymer-factor viii moiety conjugates
GB0316294D0 (en) 2003-07-11 2003-08-13 Polytherics Ltd Conjugated biological molecules and their preparation
DK2371856T3 (en) * 2004-11-12 2022-08-08 Bayer Healthcare Llc Site-directed modifikation af FVIII
AU2005322067B8 (en) * 2004-12-27 2012-07-26 Takeda Pharmaceutical Company Limited Polymer-von Willebrand factor-conjugates
WO2007126808A1 (en) * 2006-03-31 2007-11-08 Baxter International Inc Pegylated factor viii
US20100239517A1 (en) 2007-10-09 2010-09-23 Stephen Brocchini Novel conjugated proteins and peptides
KR20110016440A (ko) * 2008-04-24 2011-02-17 셀틱 파르마 피이지 엘티디. 연장된 반감기를 가진 제 ⅰⅹ 인자 접합체
ES2560807T3 (es) 2008-07-21 2016-02-22 Polytherics Limited Nuevos reactivos y procedimiento de conjugación de moléculas biológicas
GB0912485D0 (en) * 2009-07-17 2009-08-26 Polytherics Ltd Improved conjugation method

Also Published As

Publication number Publication date
IL222566A (en) 2017-12-31
GB201220667D0 (en) 2013-01-02
ZA201208989B (en) 2014-02-26
AU2011247147A1 (en) 2013-01-10
EA201290938A1 (ru) 2013-04-30
KR20130055619A (ko) 2013-05-28
WO2011135307A1 (en) 2011-11-03
MX2012012683A (es) 2013-04-03
BR112012027590A2 (pt) 2016-08-09
US20130150302A1 (en) 2013-06-13
GB2492935B8 (en) 2014-10-29
AU2011247147B2 (en) 2014-09-18
GB2492935B (en) 2014-04-30
NI201200160A (es) 2013-04-19
HK1173946A1 (en) 2013-05-31
GB2492935A8 (en) 2014-10-29
CN102939108A (zh) 2013-02-20
RU2012144555A (ru) 2014-06-10
CL2012003039A1 (es) 2014-01-24
EP2563402A1 (en) 2013-03-06
MY160922A (en) 2017-03-31
PH12012502150A1 (en) 2013-02-04
NZ603939A (en) 2013-08-30
GB2492935A (en) 2013-01-16
JP5870088B2 (ja) 2016-02-24
SG184906A1 (en) 2012-11-29
CR20120579A (es) 2013-04-25
GB201007357D0 (en) 2010-06-16
AP2012006575A0 (en) 2012-12-31
CA2797058A1 (en) 2011-11-03
ECSP12012314A (es) 2013-05-31
CO6660443A2 (es) 2013-04-30
JP2013525414A (ja) 2013-06-20
IL222566A0 (en) 2012-12-31

Similar Documents

Publication Publication Date Title
PE20130253A1 (es) Factor viia conjugado para coagulacion de la sangre
NZ603939A (en) Conjugated blood coagulation factor viii
GT201300025A (es) Derivados anticancerosos, su preparación y su aplicación en terapeútica
CR11251A (es) Depsipeptidos ciclicos y usos de los mismos
PE20120582A1 (es) Conjugados de insulina cristalina
BRPI0722061B8 (pt) uso de um polímero contendo grupo tiol e implante
EA201992610A1 (ru) Экспансия -t-клеток, композиции и способы их применения
EA201791461A1 (ru) Бензодиазепиновые димеры с мостиковым гетероариленом, их конъюгаты, способы получения и применение
CU20120170A7 (es) Compuestos y composiciones de tioacetato
EA201490582A1 (ru) Пирролбензодиазепины и конъюгаты направленного действия
EA201171480A1 (ru) Полимерные соединения-иммуномодулирующие средства
BR112012023421A2 (pt) composição farmacêutica para tratamento de aumento de pressão intraocular
EA201791744A2 (ru) Улучшенная липидная композиция
CY1118104T1 (el) Νεα κυτταροστατικα νουκλεοζιδια 7-αποαζαπουρινης
EP2569330A4 (en) CHLOROTOXIN VARIANTS AND CONJUGATES AND METHOD OF USE THEREOF
BRPI0911422B8 (pt) compostos moduladores inflamatórios antioxidantes, composição farmacêutica e usos dos mesmos
BR112014008220A2 (pt) dispositivos médicos que contêm composições de polímeros com memória de forma
CY1119274T1 (el) Μια μεθοδος και συνθεση για την καταπολεμηση εκτοπαρασιτων
CY1115774T1 (el) Υπερδιακλαδισμενα πολυανθρακικα για την διαλυτοποιηση δυσδιαλυτων δραστικων ουσιων
CO6990738A2 (es) Agentes de reversion anticoagulante
AR078113A1 (es) Composiciones agroquimicas que contienen alquil polipropilenglicolpolietilenglicol
BR112015005272A2 (pt) adutos de etanol-dicloreto de magnésio e componentes de catalisador obtidos a partir daqui
BRPI0817223B8 (pt) inibidores da interação entre mdm2 e p53, seu processo de preparação e seu uso, composição farmacêutica que os compreende e combinação
AR089068A1 (es) Composiciones para el cuidado del cabello que contiene un polimero de aminosilicona
FR2968950B1 (fr) Composition cosmetique comprenant un compose d'acide cucurbique

Legal Events

Date Code Title Description
FD Application declared void or lapsed